Caplacizumab Treatment in TTP Patients: Recovery of ADAMTS13

In this week's epside we'll learn about ADAMTS recovery after caplacizumab therapy in patients with immune thrombotic thrombocytopenic purpura. Then, we'll hear about preclinical characterization of sonrotoclax, a potential second-generation BCL2 inhibitor. Finally we'll hear about new insights into the etiology of Castleman disease where researchers describe the unusual occurrence of idiopathic multicentric Castleman disease in identical twins. 

Featured Articles: 

• ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy
• Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of
  hematologic malignancy
• Single-cell landscape of idiopathic multicentric Castleman disease in identical twins